STOCK TITAN
  1. Home
  2. Sec-filings
  3. OCUL
  4. [Form 4] OCULAR THERAPEUTIX, INC Insider Trading Activity

[Form 4] OCULAR THERAPEUTIX, INC Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ocular Therapeutix (OCUL) Executive Chairman, President and CEO Pravin Dugel reported insider transactions on Form 4. On November 24, 2025, he sold 19,530 shares of common stock at a weighted average price of $12.04 per share under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding from restricted stock units vesting on November 22, 2025. These sales were not a discretionary trade.

After this sale, he directly owned 3,157,960 shares. On November 26, 2025, his spouse transferred 49,754 shares for no consideration to the Pravin Dugel 2024 Irrevocable Trust, and the same number of shares was recorded as acquired by the trust. Following this transfer, 300,115 shares were held indirectly through the trust, and the reporting person remained the beneficial owner of those securities.

Positive

  • None.

Negative

  • None.
Insider Dugel Pravin
Role See Remarks
Sold 19,530 shs ($235K)
Type Security Shares Price Value
Gift Common Stock 49,754 $0.00 --
Gift Common Stock 49,754 $0.00 --
Sale Common Stock 19,530 $12.04 $235K
Holdings After Transaction: Common Stock — 0 shares (Indirect, By spouse); Common Stock — 3,157,960 shares (Direct)
Footnotes (1)
  1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.74 to $12.34, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. On November 26, 2025, the reporting person's spouse transferred 49,754 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dugel Pravin
(Last) (First) (Middle)
C/O OCULAR THERAPEUTIX, INC.
15 CROSBY DRIVE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/24/2025 S(1) 19,530(1) D $12.04(2) 3,157,960 D
Common Stock 11/26/2025 G(3) 49,754 D $0 0 I By spouse
Common Stock 11/26/2025 G(3) 49,754 A $0 300,115 I By Pravin Dugel 2024 Irrevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.74 to $12.34, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
3. On November 26, 2025, the reporting person's spouse transferred 49,754 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.
Remarks:
Executive Chairman, President and CEO
/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel 11/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did OCULAR THERAPEUTIX (OCUL) report on this Form 4?

The CEO, Pravin Dugel, reported selling 19,530 shares of common stock on November 24, 2025 and a 49,754-share transfer on November 26, 2025 involving his spouse and a trust.

Why did the OCUL CEO sell 19,530 shares of stock?

The 19,530 shares were sold under a durable automatic sale instruction adopted on February 21, 2024 to cover tax withholding obligations from restricted stock units vesting on November 22, 2025.

At what price were the 19,530 OCUL shares sold?

The reported weighted average sale price was $12.04 per share, with multiple transactions executed at prices ranging from $11.74 to $12.34, inclusive.

How many OCUL shares does the CEO own after these transactions?

After the reported transactions, the CEO directly owned 3,157,960 shares of common stock and indirectly 300,115 shares held through the Pravin Dugel 2024 Irrevocable Trust.

What happened with the 49,754 OCUL shares transferred on November 26, 2025?

On November 26, 2025, the reporting person’s spouse transferred 49,754 shares to the Pravin Dugel 2024 Irrevocable Trust for no consideration; the reporting person is trustee and lifetime sole beneficiary and remains the beneficial owner of those securities.

Was the OCUL CEO’s stock sale a discretionary trade?

No. The filing states the sale was executed under a durable automatic sale instruction to effect a sell-to-cover tax election, and that the sales do not represent a discretionary trade by the reporting person.